15058 The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis

2020 ◽  
Vol 83 (6) ◽  
pp. AB140
Author(s):  
Lawrence F. Eichenfield ◽  
Jonathan I. Silverberg ◽  
José-Manuel Carrascosa ◽  
Diana Rubel ◽  
Steven Watts ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Phase 3

scholarly journals Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)

2020 ◽  
Vol 4 (6) ◽  
pp. s96
Author(s):  
Eric Simpson ◽  
Andrew Blauvelt ◽  
Emma Guttman-Yassky ◽  
Margitta Worm ◽  
Charles Lynde ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Phase 3

Abstract not available.

scholarly journals Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis

2020 ◽  
Vol 4 (6) ◽  
pp. s98
Author(s):  
Jonathan I. Silverberg ◽  
Michael Cork ◽  
Andreas Wollenberg ◽  
Norito Katoh ◽  
Louise Abildgaard Steffensen ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Phase 3 ◽  
Pivotal Phase

Abstract not available.

Sign in / Sign up

Export Citation Format

Share Document